Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.04. | Citizens JMP sets $28 target for Rapport Therapeutics stock | 1 | Investing.com | ||
21.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting | 1 | GlobeNewswire (USA) | ||
11.03. | Rapport Therapeutics reports Q4 results | 3 | Seeking Alpha | ||
11.03. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
11.03. | Rapport Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
11.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
11.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 121 | GlobeNewswire (Europe) | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
03.03. | Rapport Therapeutics appoints new chief medical officer | 1 | Investing.com | ||
03.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
10.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders | 146 | GlobeNewswire (Europe) | In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical... ► Artikel lesen | |
06.12.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures | 394 | GlobeNewswire (Europe) | A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change... ► Artikel lesen | |
14.11.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
07.11.24 | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
07.11.24 | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
12.06.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement | 232 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small... ► Artikel lesen | |
07.06.24 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Pricing of Initial Public Offering | 188 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,320 | +1,41 % | DAX stabil, Gold stark: EZB-Zinsentscheid, Siemens Energy, Sartorius, Evotec, TSMC, Netflix ... | Der DAX hat sich am Mittwoch im Tagesverlauf stabilisieren können. Aus dem Handel ging er mit einem Minus von 0,5 Prozent auf 21.151 Zähler. Auch zum Start in den Donnerstag wird der deutsche Leitindex... ► Artikel lesen | |
TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
QIAGEN | 37,515 | -0,08 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
BIONTECH | 102,60 | +1,18 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren | ||
HARMONY BIOSCIENCES | 28,910 | 0,00 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
RECURSION PHARMACEUTICALS | 5,660 | +1,62 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
PRAXIS PRECISION MEDICINES | 36,590 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 39,600 | 0,00 % | MoonLake sichert sich Finanzierung von Hercules Capital in Höhe von bis zu 500 Millionen Dollar | Zug - MoonLake Immunotherapeutics, ein in der klinischen Phase befindliches Biotechnologieunternehmen, das sich auf die Entwicklung von neuartigen Therapien für Entzündungskrankheiten konzentriert,... ► Artikel lesen | |
BB BIOTECH | 29,900 | -0,50 % | BB Biotech Aktie: Vor Quartalszahlen unter Druck | BB Biotech verzeichnet deutliche Kursverluste, doch Analysten halten an positiven Erwartungen fest. Die anstehenden Quartalszahlen könnten neue Impulse bringen. Die BB Biotech-Aktie zeigt sich vor der... ► Artikel lesen |